[go: up one dir, main page]

UY24532A1 - Derivados del indazol sustituidos y compuestos relacionados - Google Patents

Derivados del indazol sustituidos y compuestos relacionados

Info

Publication number
UY24532A1
UY24532A1 UY24532A UY24532A UY24532A1 UY 24532 A1 UY24532 A1 UY 24532A1 UY 24532 A UY24532 A UY 24532A UY 24532 A UY24532 A UY 24532A UY 24532 A1 UY24532 A1 UY 24532A1
Authority
UY
Uruguay
Prior art keywords
alkyl
formula
compounds
tetrazolyl
isoxazolyl
Prior art date
Application number
UY24532A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY24532A1 publication Critical patent/UY24532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de indazol de la fórmula (I), en la que: R es H, alquilo, -(CH2)n(cicloalquilo), donde n es 0 a 2, (alcoxi)alquilo, alquenilo, -(CH2)n(heterociclilo), donde n es 0 a 2 ó -(Z')b(Z'')c(arilo), donde b y c son independientemente 0 ó 1, Z' es alquileno o alquenileno y Z'' es O, S, SO2; R1 es H, alquilo, alquenilo, fenilo, cicloalquilo; R2 se seleccciona entre el grupo de sustituyentes que se presentan en fig.2; en el que las líneas discontinuas en las fórmulas (Ia) y (Ib) representan un enlace simple o doble; m es 0 a 4; R3 es H, halógeno, ciano, alquilo, ciclopropilo; R4 es H, COOH, CN, , tetrazolilo, tiazolilo, imidazolilo, pirazolilo, oxazolilo, triazolilo, isoxazolilo; R5 es H, alquilo, CH2OH, CN, C(O)H, COOH, CONH2 o NH2; R6 es metilo, etilo; R7 es OH, SH, SO2NH2, tetrazolilo, tiazolilo, imidazolilo, oxazolilo, isoxazolilo; y a las sales farmacéuticamente aceptables de los mismos. La invención además, se refiere a los productos intermedios para la preparación de los compuestos de fórmula (I), a las composiciones farmacéuticas que los contienen y a los procedimientos de uso, de los compuestos de fórmula (I) o de las sales farmacéuticamente aceptables de los mismos, para la inhibición de la fosfodiesterasa (PDE) tipo IV y de la producción de factor de necrosis tumoral (TNF) en un mamífero y como tales son útiles en el tratamiento del asma, bronquitis, artritis. Ej. no limitante 1-(1-ciclopentil-3-etil-1H-indazol-6-il)-4-oxo-ciclohexanocarbonitrilo
UY24532A 1996-05-03 1997-04-28 Derivados del indazol sustituidos y compuestos relacionados UY24532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03

Publications (1)

Publication Number Publication Date
UY24532A1 true UY24532A1 (es) 2000-09-29

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24532A UY24532A1 (es) 1996-05-03 1997-04-28 Derivados del indazol sustituidos y compuestos relacionados

Country Status (41)

Country Link
US (2) US6211222B1 (es)
EP (1) EP0912521B1 (es)
JP (1) JP3148254B2 (es)
KR (1) KR100339935B1 (es)
CN (2) CN1112359C (es)
AP (4) AP2001002304A0 (es)
AR (1) AR006906A1 (es)
AT (1) ATE292626T1 (es)
AU (1) AU725576B2 (es)
BG (1) BG64211B1 (es)
BR (1) BR9709051A (es)
CA (2) CA2389918A1 (es)
CO (1) CO4650038A1 (es)
CZ (1) CZ292825B6 (es)
DE (1) DE69732966T2 (es)
DZ (1) DZ2217A1 (es)
EA (1) EA002272B1 (es)
ES (1) ES2238079T3 (es)
GT (1) GT199700043A (es)
HN (1) HN1997000046A (es)
HR (1) HRP970227B1 (es)
HU (1) HUP9902459A3 (es)
ID (1) ID16856A (es)
IL (2) IL126547A (es)
IS (1) IS4871A (es)
MA (1) MA24158A1 (es)
MY (1) MY132499A (es)
NO (1) NO312959B1 (es)
NZ (1) NZ332240A (es)
OA (1) OA10904A (es)
PE (1) PE64598A1 (es)
PL (1) PL329836A1 (es)
SK (1) SK148298A3 (es)
TN (1) TNSN97070A1 (es)
TR (1) TR199802202T2 (es)
TW (1) TW449585B (es)
UA (1) UA65536C2 (es)
UY (1) UY24532A1 (es)
WO (1) WO1997042174A1 (es)
YU (1) YU16397A (es)
ZA (1) ZA973804B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
PT983249E (pt) 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos
EA200000385A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
EA200000488A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Замена катехина на биоизостеру индазола в терапевтически активных соединениях
IL126745A (en) 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
IL132407A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6303782B1 (en) * 1999-04-20 2001-10-16 Pfizer Inc Process for preparing benzylnitriles
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
WO2003051344A1 (en) 2001-12-14 2003-06-26 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation_using a non-polypeptide camp level modulator
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8277809B2 (en) * 2006-04-21 2012-10-02 Centocor, Inc. CXCL13 antagonists and their use for the treatment of inflammatory diseases
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (es) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
EP0630367B1 (en) * 1992-03-09 2000-07-05 Zeneca Limited Novel arylindazoles and their use as herbicides
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
EP0787132A1 (en) * 1994-10-20 1997-08-06 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
JPH10509469A (ja) * 1994-10-21 1998-09-14 エリシャ・テクノロジーズ・カンパニー・エルエルシー 金属製造物のための腐食抵抗緩衝系
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
PT983249E (pt) * 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos

Also Published As

Publication number Publication date
UA65536C2 (en) 2004-04-15
IL152083A0 (en) 2003-05-29
YU16397A (sh) 1999-12-27
MA24158A1 (fr) 1997-12-31
HRP970227A2 (en) 2000-12-31
OA10904A (en) 2001-10-11
CZ292825B6 (cs) 2003-12-17
JPH11508284A (ja) 1999-07-21
AP2001002304A0 (en) 2001-12-31
DE69732966T2 (de) 2005-09-08
HN1997000046A (es) 1997-06-26
AP1147A (en) 2003-02-25
NZ332240A (en) 2000-07-28
EP0912521A1 (en) 1999-05-06
CN1112359C (zh) 2003-06-25
CN1217714A (zh) 1999-05-26
AP1146A (en) 2003-02-25
CA2252982C (en) 2002-10-08
CA2389918A1 (en) 1997-11-13
AU1937397A (en) 1997-11-26
SK148298A3 (en) 2000-02-14
TR199802202T2 (xx) 1999-02-22
DZ2217A1 (fr) 2002-12-03
PL329836A1 (en) 1999-04-12
AP2001002294A0 (en) 2001-12-31
ES2238079T3 (es) 2005-08-16
CO4650038A1 (es) 1998-09-03
EA002272B1 (ru) 2002-02-28
AU725576B2 (en) 2000-10-12
US6127398A (en) 2000-10-03
AP9700975A0 (en) 1997-07-31
JP3148254B2 (ja) 2001-03-19
HRP970227B1 (en) 2002-06-30
HUP9902459A3 (en) 2001-10-29
BG64211B1 (bg) 2004-05-31
ZA973804B (en) 1998-11-02
IL126547A (en) 2003-03-12
CA2252982A1 (en) 1997-11-13
NO312959B1 (no) 2002-07-22
TNSN97070A1 (fr) 2005-03-15
KR100339935B1 (ko) 2002-07-18
ID16856A (id) 1997-11-13
CZ349298A3 (cs) 1999-09-15
EA199800882A1 (ru) 1999-06-24
CN1422849A (zh) 2003-06-11
AR006906A1 (es) 1999-09-29
US6211222B1 (en) 2001-04-03
HUP9902459A2 (hu) 1999-11-29
EP0912521B1 (en) 2005-04-06
DE69732966D1 (de) 2005-05-12
KR20000010751A (ko) 2000-02-25
WO1997042174A1 (en) 1997-11-13
IL126547A0 (en) 1999-08-17
PE64598A1 (es) 1998-10-26
ATE292626T1 (de) 2005-04-15
HK1019443A1 (en) 2000-02-11
GT199700043A (es) 1998-10-02
BR9709051A (pt) 1999-08-03
TW449585B (en) 2001-08-11
NO985095L (no) 1998-12-29
BG102946A (en) 1999-11-30
AP0102304A0 (en) 1997-11-03
MY132499A (en) 2007-10-31
NO985095D0 (no) 1998-11-02
IS4871A (is) 1998-10-16

Similar Documents

Publication Publication Date Title
UY24532A1 (es) Derivados del indazol sustituidos y compuestos relacionados
JP7164542B2 (ja) 新規な化合物であるｙａｐ／ｔａｚ－ｔｅａｄ相互作用阻害剤、および悪性中皮腫の治療でのその使用
ES2339456T3 (es) Derivados de pirrol(2,3-b)piridina activos como inhibidores de quinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
US7300917B2 (en) Remedy for chronic disease
US8124645B2 (en) LPA receptor antagonist
ES2341540T3 (es) Derivados de 1h-1,2,4-triazol-3-carboxamida como ligandos de receptores de canabinoide cb1.
AU2007260529B2 (en) Indoline amide derivatives as EP4 receptor ligands
AR007456A1 (es) Compuestos derivados de indazol sustituido y composiciones farmaceuticas que lo contienen
CA2599348A1 (en) Indole compound and use thereof
ES2379656T3 (es) Inhibidores de cinasas y procedimientos de utilización de los mismos
ES2533971T3 (es) Derivados de bencimidazol útiles en el tratamiento de trastornos relacionados con el receptor vaniloide TRPV1
AU2002349432A1 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
AR008162A1 (es) Compuestos activos derivados de indazol sustituido, composiciones farmaceuticas que los contienen y compuesto util para su preparacion
AR035716A1 (es) Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos
WO2004002531A1 (ja) 血管の収縮または拡張による疾患治療剤
EP3045445A1 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
EP1829874B1 (en) Tricyclic compound and use thereof
JPWO2006025324A1 (ja) トロパン化合物およびそれらを有効成分として含有する医薬組成物
JP2019523230A (ja) 抗転移性２Ｈ‐セレノフェノ［３，２‐ｈ］クロメン、それらの合成、および同薬剤の使用方法
JP4828142B2 (ja) 新規な融合ピラゾリル化合物
ES2640800T3 (es) Imidazolcarboxamidas y su uso como inhibidores de la FAAH
WO2005021518A1 (ja) 縮環化合物およびその用途
MX2007002624A (es) Fenoles de fenantridina carbonilo como moduladores de citocina.
WO2007086554A1 (ja) トロパン化合物およびそれらを有効成分として含有する医薬組成物
ECSP972158A (es) Analogos de indazol sustituido

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170428